HFM
ALXN

Harvest Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Harvest Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-173
Closed -$32K – 836
2021
Q2 		$32K Hold
173
– – ﹤0.01% 551
2021
Q1 		$26K Sell
173
-97
-36% -$15K ﹤0.01% 606
2020
Q4 		$42K Buy
+270
New +$34.7K ﹤0.01% 389
2019
Q3 		– Sell
-1,346
Closed -$176K – 463
2019
Q2 		$176K Buy
1,346
+872
+184% +$112K 0.02% 128
2019
Q1 		$64K Buy
+474
New +$58.9K 0.01% 249
2017
Q4 		– Sell
-536
Closed -$75K – 257
2017
Q3 		$75K Buy
536
+209
+64% +$28.4K 0.01% 118
2017
Q2 		$40K Buy
+327
New +$38.1K 0.01% 174

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Harvest Fund Management's ALXN Position: Q3 2021 in Review

Harvest Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 173 shares — an estimated $32K sold.

Harvest Fund Management first reported a position in ALXN in Q2 2017 and held it in 7 quarters. The position peaked at $176K in Q2 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Harvest Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Harvest Fund Management sold 173 Alexion Pharmaceuticals shares in Q3 2021, an estimated $32K.
  • Harvest Fund Management first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 7 quarters.
  • Harvest Fund Management's Alexion Pharmaceuticals position peaked at $176K in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Harvest Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.